Summary
Global Markets Direct’s, ‘Bacterial Conjunctivitis - Pipeline Review, H1 2016’, provides an overview of the Bacterial Conjunctivitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis
- The report reviews pipeline therapeutics for Bacterial Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bacterial Conjunctivitis therapeutics and enlists all their major and minor projects
- The report assesses Bacterial Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bacterial Conjunctivitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bacterial Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Cellceutix Corporation
Daiichi Sankyo Company, Limited
InSite Vision Incorporated
NovaBay Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Senju Pharmaceutical Co., Ltd.
Shire Plc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Conjunctivitis Overview 6
Therapeutics Development 7
Pipeline Products for Bacterial Conjunctivitis - Overview 7
Bacterial Conjunctivitis - Therapeutics under Development by Companies 8
Bacterial Conjunctivitis - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Bacterial Conjunctivitis - Products under Development by Companies 12
Bacterial Conjunctivitis - Companies Involved in Therapeutics Development 13
Cellceutix Corporation 13
Daiichi Sankyo Company, Limited 14
InSite Vision Incorporated 15
NovaBay Pharmaceuticals, Inc. 16
Ocular Therapeutix, Inc. 17
Senju Pharmaceutical Co., Ltd. 18
Shire Plc 19
Bacterial Conjunctivitis - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
auriclosene - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
azithromycin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
azithromycin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
brilacidin tetrahydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISV-405 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
levofloxacin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
moxifloxacin hydrochloride SR - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SHP-640 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
vancomycin hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Bacterial Conjunctivitis - Recent Pipeline Updates 40
Bacterial Conjunctivitis - Dormant Projects 55
Bacterial Conjunctivitis - Product Development Milestones 56
Featured News & Press Releases 56
Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses 56
Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical 57
Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US 57
Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops 57
Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops 58
Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma 58
Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco 58
Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision 59
Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco 59
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61
List of Tables
Number of Products under Development for Bacterial Conjunctivitis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Bacterial Conjunctivitis - Pipeline by Cellceutix Corporation, H1 2016 13
Bacterial Conjunctivitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 14
Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H1 2016 15
Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2016 16
Bacterial Conjunctivitis - Pipeline by Ocular Therapeutix, Inc., H1 2016 17
Bacterial Conjunctivitis - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 18
Bacterial Conjunctivitis - Pipeline by Shire Plc, H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 27
Bacterial Conjunctivitis Therapeutics - Recent Pipeline Updates, H1 2016 40
Bacterial Conjunctivitis - Dormant Projects, H1 2016 55
List of Figures
Number of Products under Development for Bacterial Conjunctivitis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 27
